TY - JOUR
T1 - Characteristics and prognostic impact of IDH mutations in AML
T2 - a COG, SWOG, and ECOG analysis
AU - Zarnegar-Lumley, Sara
AU - Alonzo, Todd A.
AU - Gerbing, Robert B.
AU - Othus, Megan
AU - Sun, Zhuoxin
AU - Ries, Rhonda E.
AU - Wang, Jim
AU - Leonti, Amanda
AU - Kutny, Matthew A.
AU - Ostronoff, Fabiana
AU - Radich, Jerald P.
AU - Appelbaum, Frederick R.
AU - Pogosova-Agadjanyan, Era L.
AU - O’Dwyer, Kristen
AU - Tallman, Martin S.
AU - Litzow, Mark
AU - Atallah, Ehab
AU - Cooper, Todd M.
AU - Aplenc, Richard A.
AU - Abdel-Wahab, Omar
AU - Gamis, Alan S.
AU - Luger, Selina
AU - Erba, Harry
AU - Levine, Ross
AU - Kolb, E. Anders
AU - Stirewalt, Derek L.
AU - Meshinchi, Soheil
AU - Tarlock, Katherine
N1 - Publisher Copyright:
© 2023 American Society of Hematology. All rights reserved.
PY - 2023/10/10
Y1 - 2023/10/10
N2 - Somatic mutations in isocitrate dehydrogenase (IDH) genes occur frequently in adult acute myeloid leukemia (AML) and less commonly in pediatric AML. The objective of this study was to describe the prevalence, mutational profile, and prognostic significance of IDH mutations in AML across age. Our cohort included 3141 patients aged between <1 month and 88 years treated on Children’s Cancer Group/Children’s Oncology Group (n = 1872), Southwest Oncology Group (n = 359), Eastern Cooperative Oncology Group (n = 397) trials, and in Beat AML (n = 333) and The Cancer Genome Atlas (n = 180) genomic characterization cohorts. We retrospectively analyzed patients in 4 age groups (age range, n): pediatric (0-17, 1744), adolescent/young adult (18-39, 444), intermediate-age (40-59, 640), older (≥60, 309). IDH mutations (IDHmut) were identified in 9.2% of the total cohort (n = 288; IDH1 [n = 123, 42.7%]; IDH2 [n = 165, 57.3%]) and were strongly correlated with increased age: 3.4% pediatric vs 21% older, P < .001. Outcomes were similar in IDHmut and IDH-wildtype (IDHWT) AML (event-free survival [EFS]: 35.6% vs 40.0%, P = .368; overall survival [OS]: 50.3% vs 55.4%, P = .196). IDH mutations frequently occurred with NPM1 (47.2%), DNMT3A (29.3%), and FLT3-internal tandem duplication (ITD) (22.4%)
AB - Somatic mutations in isocitrate dehydrogenase (IDH) genes occur frequently in adult acute myeloid leukemia (AML) and less commonly in pediatric AML. The objective of this study was to describe the prevalence, mutational profile, and prognostic significance of IDH mutations in AML across age. Our cohort included 3141 patients aged between <1 month and 88 years treated on Children’s Cancer Group/Children’s Oncology Group (n = 1872), Southwest Oncology Group (n = 359), Eastern Cooperative Oncology Group (n = 397) trials, and in Beat AML (n = 333) and The Cancer Genome Atlas (n = 180) genomic characterization cohorts. We retrospectively analyzed patients in 4 age groups (age range, n): pediatric (0-17, 1744), adolescent/young adult (18-39, 444), intermediate-age (40-59, 640), older (≥60, 309). IDH mutations (IDHmut) were identified in 9.2% of the total cohort (n = 288; IDH1 [n = 123, 42.7%]; IDH2 [n = 165, 57.3%]) and were strongly correlated with increased age: 3.4% pediatric vs 21% older, P < .001. Outcomes were similar in IDHmut and IDH-wildtype (IDHWT) AML (event-free survival [EFS]: 35.6% vs 40.0%, P = .368; overall survival [OS]: 50.3% vs 55.4%, P = .196). IDH mutations frequently occurred with NPM1 (47.2%), DNMT3A (29.3%), and FLT3-internal tandem duplication (ITD) (22.4%)
UR - http://www.scopus.com/inward/record.url?scp=85174324824&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85174324824&partnerID=8YFLogxK
U2 - 10.1182/BLOODADVANCES.2022008282
DO - 10.1182/BLOODADVANCES.2022008282
M3 - Article
C2 - 37267439
AN - SCOPUS:85174324824
SN - 2473-9529
VL - 7
SP - 5941
EP - 5953
JO - Blood Advances
JF - Blood Advances
IS - 19
ER -